CAPTRUST Financial Advisors
ONCT

CAPTRUST Financial Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36
Closed -$3K – 4974
2021
Q3 		$3K Hold
36
– – ﹤0.01% 4173
2021
Q2 		$3K Hold
36
– – ﹤0.01% 4076
2021
Q1 		$6K Buy
+36
New +$4.76K ﹤0.01% 3682

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM

CAPTRUST Financial Advisors's ONCT Position: Q4 2021 in Review

CAPTRUST Financial Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2021, closing a stake of 36 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in ONCT in Q1 2021 and held it in 3 quarters. The position peaked at $6K in Q1 2021. 82 funds tracked by Wall St. Rank hold ONCT as of Q4 2021.

  • CAPTRUST Financial Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 36 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.